Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

Yared J. A.; Hardy N.; Singh Z.; Hajj S.; Badros A. Z.; Kocoglu M.; Yanovich S.; Sausville E. A.; Ujjani C.; Ruehle K.; Goecke C.; Landau M.; Rapoport A. P.

首页> 外文期刊>Bone marrow transplantation >Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

【24h】

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

机译：同种异体干细胞移植后复发/难治性霍奇金淋巴瘤对尼古鲁单抗的主要临床反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bone marrow transplantation》 |2016年第6期|共3页
作者
Yared J. A.; Hardy N.; Singh Z.; Hajj S.; Badros A. Z.; Kocoglu M.; Yanovich S.; Sausville E. A.; Ujjani C.; Ruehle K.; Goecke C.; Landau M.; Rapoport A. P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation [J] . Yared J. A., Hardy N., Singh Z., Bone marrow transplantation . 2016,第6期

机译：同种异体干细胞移植后复发/难治性霍奇金淋巴瘤对尼古鲁单抗的主要临床反应
2. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [J] . Jeon Young-Woo, Yoon Seugyun, Min Gi June, Clinical lymphoma, myeloma & leukemia . 2019,第6期

机译：氟甲滨和梅洛兰的临床结果与难治性或复发的腐蚀性非霍奇金淋巴瘤患者发生了800 CGY全身辐照调理方案，接受同种异体造血干细胞移植
3. Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma. [J] . Paillard C, Salmon A, Curtillet C, Pediatric transplantation. . 2010,第1期

机译：强度降低的同种异体造血干细胞移植强度降低的异体造血干细胞移植后一年的临床反应的证据，这些患者患有侵袭性难治性霍奇金淋巴瘤。
4. CLINICAL EVALUATION OF A CD40-ACTIVATED B CELL VACCINE TO PREVENT LYMPHOMA RELAPSE INDOGS [C] . Nicola J. Mason Conference of the American College of Veterinary Internal Medicine . 2014

机译：CD40活化B细胞疫苗的临床评价，以防止犬淋巴瘤复发
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation [O] . Anna Sureda, Carme Canals, Reyes Arranz, 2012

机译：复发或难治性霍奇金淋巴瘤患者降低强度条件后进行同种异体干细胞移植。 HDR-ALLO研究的结果–一项由GrupoEspañolde Linfomas / Trasplante deMédulaOsea（GEL / TAMO）和欧洲血液和骨髓移植小组淋巴瘤工作组进行的前瞻性临床试验
7. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation [O] . J A Yared, N Hardy, Z Singh, 2016

机译：同种异体干细胞移植后复发/难治性Hodgkin淋巴瘤对Nivolumab的主要临床反应

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

著录项

相似文献

相关主题

期刊订阅